Four over 100 million products and two heavy new drugs. Does this enterprise want to lead the nervous system drug market?

Highlights recently, Denmark Lingbei pharmaceutical announced that its innovative drug lesagilan mesylate (trade name: anzilar ®) was officially launched in China Another innovative drug, voltacetin hydrobromide (trade name: xindayue ®), has been approved by CFDA and will be launched in China in the second quarter of 2018 Since Lingbei officially entered China in 2007, it has launched four heavy-duty products in succession With the help of cooperative marketing mode, Lingbei has become a leader in the field of nervous system medicine Now, with the launch of several heavy-duty new drugs in succession, can Lingbei become a leader in the field of nervous system medicine; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant;"> Voltacetin hydrobromide tablets are listed for the first time in China The product of Linbei to be listed in China, voltacetin hydrobromide tablets (trade name: xindayue ®), is an antidepressant drug mainly used for adult severe depression According to midnet Med According to the statistics of drug review database, the product was undertaken by CDE (drug review center) on December 21, 2016, and was approved for import on November 29, 2017, which is the first time that fosixidine hydrobromide tablets have been approved for market in China Table 1: review results of the application for marketing of voltacetin hydrobromide tablets source: Med drug review database of minenet Voltacetin is the first antidepressant with a variety of pharmacological activities, which not only helps to improve the emotional symptoms of patients with depression, but also improves the cognitive symptoms of patients independent of emotion The listing of xindayue ® is another milestone in the innovative research and development of antidepressant drugs in Lingbei, which has opened a new era of multi-dimensional, multi-mode machine-made antidepressant treatment It is reported that fosixtine hydrobromide tablets were approved by FDA in 2013 to treat depression, and have been listed in more than 70 countries and regions in the world, including the United States and the European Union   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> in the past decade, three products have dominated the antidepressant market Lingbei company is a global pharmaceutical company focusing on the field of mental and nervous system, focusing on depression, schizophrenia, Alzheimer's disease and Parkinson's disease According to the data of minenet, in 2016, the market scale of terminal antidepressant chemicals in public medical institutions in China reached 5.77 billion yuan, an increase of 4.73% over the previous year According to the pattern of terminal antidepressant chemical manufacturers in China's public medical institutions in 2016, Pfizer, Lingbei, Lilai, Jingwei pharmaceutical and Huahai pharmaceutical accounted for more than half of the total antidepressant market share, with Lingbei ranking second with 13.25% of the total Figure 1: China's public medical institutions' terminal antidepressant chemical drug market (unit: 10000 yuan) in 2013-2016 Figure 2: China's public medical institutions' terminal antidepressant chemical manufacturers in 2016 Lingbei officially entered China in 2007, and achieved such good performance in just ten years, which is mainly attributed to three heavy-duty products that have been listed in China, including Flupentixol melitracen tablets (trade name: delixin ®), escitalopram oxalate tablets (trade name: lespar ®), and citalopram hydrobromide tablets (trade name: shipmex ®) Table 2: Sales of Deanxit, shipumi and lespex at the terminals of public medical institutions in 2016 (unit: 10000 yuan) Deanxit, commonly known as Flupentixol tablets, is a mixture composed of two compounds, of which Flupentixol is a neuroblocker with anti anxiety and anti depression effects in a small dose; Melitracen is a biphasic antidepressant with low dose and excitability The mixture of the two compounds was used in adults with mild and severe depression and anxiety According to the data of mienei.com, in 2016, the sales volume of delixin, the terminal of public medical institutions in China, was close to 800 million yuan, an increase of 3.33% over the previous year, occupying 96.9% of the market share of the whole droperidol ton meritrasin, far ahead of other manufacturers Figure 3: in 2016, China's public medical institutions terminal flupentixicillin manufacturer pattern lespar, commonly known as escitalopram tablets, was jointly developed by Lingbei and forest pharmaceutical Its tartrate was first listed in the United States in 2002 Escitalopram has the effect of enhancing the central nervous system 5-HT energy, thus inhibiting the re uptake of 5-HT, and achieving the effect of anti depression According to the data of mienei.com, in 2016, the sales volume of the terminal of China's public medical institutions reached 550 million yuan, an increase of 7.9% over the previous year, accounting for 44.4% of the whole market share of escitalopram Figure 4: in 2016, China's city public medical institutions terminal manufacturer of escitalopram, sipromil, commonly known as citalopram tablets, is a highly selective 5-HT reuptake inhibitor, which has the highest selectivity for 5-HT reuptake inhibition among similar drugs After being approved for marketing in the United States in 1998, it has become the fastest-growing antidepressant in the U.S market According to the data of mienei.com, in 2016, the sales volume of the terminal of China's public medical institutions reached 200 million yuan, an increase of 5.3% over the previous year, accounting for 67.34% of the total market share of citalopram Figure 5: 2016 China's public medical institutions terminal citalopram manufacturer pattern none = "shifumousedownstyle ('shifu_bus_002 ')" style = "margin: 1em Auto; padding: 0px; max width: 100%; color: rgb (62, 62, 62); font family:" hiragino sans GB "," Microsoft YaHei ", Arial, sans serif; font size: 16px; line height: 25.6px; width: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> there are many projects under research, and Lingbei has successively launched new products in the Chinese market It has been adopting the mode of cooperative marketing, and its products have been represented to other pharmaceutical enterprises For example, Flupentixol and Melitracen Tablets is marketed by kangzhe Pharmaceutical Co., Ltd., and Escitalopram Oxalate Tablets is marketed by Xi'an Yang Sen, a pharmaceutical subsidiary of Johnson & Johnson in China Because of this business model of cooperative marketing, Lingbei has more energy and time to invest in the research and development of new drugs According to the global R & D database of minenet, in addition to depression, Lingbei will have new drugs on the market in Parkinson's disease, Alzheimer's disease and other fields in the future, such as the declared namefen hydrochloride tablets, luaa21004 tablets, sheindole tablets, woxetine hydrobromide tablets, and l-spin tablets Five kinds of imported drugs of citalopram tablets have been approved for clinical use Table 3: list of drugs under research in Lingbei: Source: none = "shifumousedown ('shifu_t_002 ')" style = "margin: 1em Auto; padding: 0.5em 0px; max width: 100%; color: rgb (62, 62, 62); font family:" hiragino sans GB "," Microsoft YaHei ", Arial, sans serif; font size: 16px; line height: 25.6px; width: 1; border: none; text-align: center; width: 670px; box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> Jieyu Lingbei takes the nervous system medicine as its own field of deep cultivation, and now it has achieved fruitful results With the annual growth of the nervous system medicine market, the continuous improvement of people's living standards, and the improvement of people's cognitive level of nervous diseases, it is believed that the drugs that have been on the market or will be on the market in recent years will bring rich returns to the company.